Parsa-Kondelaji Mohammad, Mansouritorghabeh Hassan
Experimental Hematology and Blood Banking, Mashhad University of Medical Sciences, Mashhad, Iran.
Central Diagnostic Laboratories, Mashhad University of Medical Sciences, Ghaem Hospital, Mashhad, Iran.
Thromb J. 2023 Jul 27;21(1):79. doi: 10.1186/s12959-023-00522-2.
Antiplatelet drugs, such as Aspirin and Clopidogrel (Plavix) are effective in the primary prevention of thromboembolic events. They are commonly used to reduce the risk of recurrence of thromboembolism. The body's hemostatic system responds differently to these drugs in different people. Resistance testing for aspirin and Clopidogrel is now recommended before starting antiplatelet therapy.
A systematic literature search was performed on May 12, 2021, using the medical search engines PubMed, Scopus, and Web of Science, and the local databases SID and Magiran. After data extraction, a meta-analysis was performed using Comprehensive Meta-Analysis (CMA2) software. The I2 statistic was used to measure heterogeneity between estimates.
Among the 949 papers, Clopidogrel resistance was assessed in 136 patients and Aspirin resistance in 400 patients. The prevalence of Aspirin resistance was found to be 52.1% and the prevalence of Clopidogrel resistance was found to be 20.5%.
It seems that in Iran, the issue of Aspirin and Clopidogrel resistance is suboptimally addressed. This pattern could also occur in other developing countries in the Middle East region.
抗血小板药物，如阿司匹林和氯吡格雷（波立维），在血栓栓塞事件的一级预防中有效。它们常用于降低血栓栓塞复发的风险。人体的止血系统在不同个体中对这些药物的反应不同。现在建议在开始抗血小板治疗前进行阿司匹林和氯吡格雷的抵抗检测。
于2021年5月12日使用医学搜索引擎PubMed、Scopus和Web of Science以及本地数据库SID和Magiran进行了系统的文献检索。数据提取后，使用综合荟萃分析（CMA2）软件进行荟萃分析。I2统计量用于衡量估计值之间的异质性。
在949篇论文中，对136例患者评估了氯吡格雷抵抗，对400例患者评估了阿司匹林抵抗。发现阿司匹林抵抗的患病率为52.1%，氯吡格雷抵抗的患病率为20.5%。
在伊朗，阿司匹林和氯吡格雷抵抗问题似乎未得到充分解决。这种情况在中东地区的其他发展中国家也可能出现。
